Source file signed link, expires in 15 minutes
Extracted text 15
Page 1
PT Diagnos Laboratorium Utama, Tbk (DGNS) Newsletter Q-3 2025 Update
Page 2
3Q2025 Performance Highlight
Quarterly Report
3Q 2025
Description Unit 3Q2024 2Q2025 3Q2025 % YoY % QoQ
Key Notes
PROFIT LOSS STATEMENT
Revenue IDR 42.310 39.685 41.393 -2% 4% Business Performance by 3Q2025
COGS (exclude depreciation) IDR 22.507 20.070 20.080 -11% 0% • DGNS recorded -2% yoy Revenue, due to decline in revenue / test value
in respect to promotional activities in several high value testing
Gross Profit (Exlude Depreciation) IDR 19.803 19.614 21.313 8% 9%
Gross Profit Margin Percent 47% 50% 51%
• Gross Profit Margin expanded by 1% even total volume increased by 3%
OPEX (exclude depreciation) IDR 16.424 16.557 17.768 8% 7% (raw material cost to total revenue from 29% to 28% and 3rd party
referral to revenue from 9,11% to 4,65%) in respect to:
EBITDA IDR 3.379 3.058 3.545 5% 16% • Test consolidation program by implementing diagnos central labs,
EBITDA Margin Percent 7,99% 7,71% 8,56% • Implementation of new inhouse non laboratory equipment
• New CPRR mechanism implementation due to negotiation with
Depreciation & Amortization IDR 3.656 3.650 3.011 -18% -17% several key vendor
EBIT IDR (277) (592) 534 -293% -190%
EBIT Margin Percent (1%) 5% 1%
Other Income IDR 187 627 476 155% -24%
Net Interest Expenses IDR (599) (440) (343) -43% -22%
EBT IDR (689) (405) 667 197% 265%
Taxes IDR - - - 0% 0%
Net Income/(loss) IDR (689) (405) 667 197% 265%
NP Margin Percent (2%) 3% 2%
Laboratories Product & Volume
Total Volume Test 225.800 216.818 231.837 3% 7%
Test Offering
Total Menu Test Menu 1.855 2.085 2.576
Total New Product Launching Menu 702 32 29
Lab & Clinic Presence
Stand Alone Laboratories Outlet 5 4 4
Outlet & Collection Point Outlet 20 27 30
Clinics - 1 1
Total All Diagnos Outlet 25 32 35
Page 3
Company Overview
Page 4
As part of BMHS Group centres of Excellence, Diagnos Bring Trusted clinical excellence through
30+ labs Presence Across Indonesia
BMHS (Bundamedik) Group of Companies to form the most
comprehensive lifestyle health care provider in Indonesia Key Highlights
• Diagnos is publicly listed clinical laboratory company with national coverage,
transforming into a digitally connected healthcare platform through diagnostics and
clinics (Ticker: DGNS)
• Operate 30+ labs across 4 major island
IVF Diagnostic
Clinics • Expanding into new territories of specialized clinics to deal with NC metabolic disease
Lab
and woman health clinics
• Molecular & Genomic Testing, clinical & surgical pathology as centers of excellence
Specialty Emergency
Hospital Response
Strong Management Team with Proven Track Record in Healthcare Industry
He is one of the pioneer of the IVF Industry and continues to actively
practice as one of Indonesia’s most celebrated obstetrics and
Hospital Pharmacy
gynecology physicians. He has long pursued business ventures in
the healthcare sector and has since expanded into the biotech and
aggrotech business
Dental Dr. dr. Ivan Rizal Sini, MD,FRANZCOG, GDRM, SpOG
BIC Clinics Clinic President Commissioner
He is a well-respected businessman and investor with broad
Medical exposure across multiple industries. He began his business
Tourism Physiotherapy endeavors in the mining industry and has long expanded into other
Board
sectors such as health care, real estate and property, construction,
and consumer service and product
Ir. Mesha Rizal Sini
Director
Page 5
Extensive List Of Test Offered Within Our Integrated Lab
Ecosystem
Diagnos
Institute
Excellent
Laboratory
Walk In Corporate Service Home Service
Research Support Clinical Service
Integrated Clinical Laboratory Ecosystem
Diagnos focusing in delivering high quality clinical diagnostics services that
are consistent, trustworthy and reliable to all partners and customers.
We offer a wide range integrated laboratory services that best suites in class
facilities and infrastructure support.
Digital
Integration
Page 6
Our Stand-Alone Facilities Across Major Island in Indonesia
Klinik Utama Diagnos Diagnos Ciputat Diagnos Denpasar
Healthcare Jalan R.E Martadinata no 28 Jalan Diponegoro no 147 Dauh
Ciputat, Tangerang Selatan, Puri Klod, Denpasar Barat, 80114
Jalan Teuki Cik Ditiro No. 11
15411
Menteng, Jakarta Pusat, 10350
Call Center Diagnos
Graha Anam Lt. 2 Jl. Teuku Cik Ditiro
No. 11 A-C Menteng Jakarta Pusat
Diagnos Padang Diagnos Makassar Diagnos Batam
Jalan Proklamasi no 39, RT 8 RW 2 Jalan Urip Sumoharjo no 90 Sinrijala, Jl. Abulyatama Ruko UNIBA, Blk. B No.12,
Alang Laweh, Kota Padang, 25211 Kota Makassar, 90144 Belian, Kec. Batam, Kota Batam,
Kepulauan Riau 29432
Page 7
DOMESTIC & INTERNATIONAL RECOGNITION ON DELIVERING CLINICAL LAB SERVICES Quality Management To provide quality services to customers, we continuously to innovate and are currently accredited by : 1. ISO 45001:2018 : Management, Administration and The Provision of Clinical Laboratory Services 2. ISO 15189 : For Clinical Laboratory Competence and Quality 3. ISO 9001:2015 : Quality Management System 4. RS (SNARS 2012) : Diagnos in hospitals 5. ACHS International accreditation : Diagnos in hospitals
Page 8
Market Overview & Growth Strategies
Page 9
Indonesia’s Aging Population Signals Surging Demand for Chronic Disease Care, Creating
Opportunities for Scalable, patient-centered healthcare solution for preventive care
AGING POPULATION DRIVES POTENTIAL UNTAPPED HEALTH CONSUMPTION
Indonesian Older Population in Mn 21,10%
As Indonesia's population ages, the prevalence of
15,77% chronic disease is rising in parallel
331
9,70%
7,56%
306 %
39
38
37
36
267 35
34
241 % Population Aged 60+
Hypertension Prevalence (%)
19.9
18
Cardiovascular Disease Prevalence
15.7
14.3 (%)
12.5
10.7 16 Diabetes Prevalence (%)
15.5
14.5
13
10.9 11.7
7 7.5
6 6.5
70 5.5
5
48 2020 2025 2030 2035 2040 2045
26 Source: BPS Indonesia population Projection (2020-2045), Riskesdas 2018, IDF Diabetes Atlas 2023, Scientific
18
Report 2024
Population aging is a key driver of Indonesia’s rising chronic disease burden, as
2010 2019 2035E 2050E
people live longer, they are more likely to develop non-communicable disease –
Indonesian demographic is undergoing a significant transformation a trend reflected in national statistics which show significant upticks observed
characterized by a notable increase in the proportion of elderly citizens aged 60 in both the middle-aged and elderly populations.
and above. Increasing the demand for integrated patient centric chronic
disease care
Page 10
Diagnos is Evolving Beyond a Lab Operator to Lead Indonesia’s Integrated Healthcare Ecosystem
Proactively to Aging demographics and Rising Chronic Disease Burden
Diagnos Is Evolving into a Comprehensive Healthcare Ecosystem. Leveraging tiered model of
clinics, labs, and diagnostics referral acquisitions, anchored by our national center of excellence
How Diagnos Multi-Tiered Ecosystem of Clinics & Lab
Empower Each Other
Top Tier :
National Centers of Excellence External Lab Partners
Outlet
Gen
CP
CEX
Test IDPT
CPX
Ref. Lab
Test
CPX
Ref.
Oncology National
Molecular Reference
Centers Laboratory
CPT MTG
Mid Tier : Oncology National
Specialized Occupational
Specialized Clinics Clinic Clinic Center Ref Lab
Independent Laboratories
Foundational Layer: Clinic
Third Party Clinics & Hospitals Strategic Clinic
Specialized Clinics Occ.
Comm
Partnership / Acquisitions Through Health
Health
• Laboratory Outlet Development
• Diagnostics Test Referral System
Page 11
This Hybrid model leverages our national lab network and digital tools to deliver targeted
clinics, telehealth, and data driven care, creating scalable impact in both tier-1 and tier2 cities
Existing Presence:
• 5 Branch – Batam, Padang,
Ciputat, Denpasar, Makassar STRATEGIC EXPANSION OF DIAGNOS HEALTHCARE NETWORK
• 31 Outlet – West Sumatra, Riau,
South Sumatra, Banten, West Diagnos is executing a dual-tier national expansion strategy to build a
Java, Central Java, East Java, scalable healthcare presence through:
Nusa Penida
• 1 Clinic - Jakarta • Flagship Specialty clinic in tier-1 cities serving as innovation hub,
delivering premium care, telehealth, and chronic disease
management
• Stand alone laboratories in Tier-2 & Tier-3 Cities extend diagnostic
reach, enabling fast, affordable and high-quality testing across
underserved region
New Outlet:
RSIA Andini
Pekanbaru
New Outlet:
RSU Bunda
Padang
Targeted Area of expansion:
• Medan – North Sumatera
• Palembang – South Sumatera
• Pekanbaru – Riau
• Bandung – West Java
Specialized Clinic • Bekasi – West Java
• Bogor – West Java
Flagship Specialty clinic
New Outlet:
• Tangerang – Banten
Diagnos • DKI Jakarta
Helix Depok
• Semarang – Central Java
Stand Alone Laboratorium
• Surabaya – East Java
Independent Lab Network • Yogyajakarta
New Outlet: Nusa
Medica Clinic • Manado – North Sulawesi
• Denpasar - Bali
Page 12
FIRO is Driving Product Innovation to Lead in Woman’s, Maternal, and Child Health Diagnostics
across All Life Stages
Diagnos is proud to be part of the BMHS Ecosystem, so we focus on developing products that strengthen our specialization in Women’s, maternal, and child
health as our core target market for our clinical laboratory product
Life Stage : Pre-conception Life Stage : Pregnancy Life Stage : New-Born / Infant
Fertility Planning, Reproductive Fetal genetic / chromosomal
Health screening for rare disease Genetic screening, Early disease
detection
Fertility Infectious Disease
Product Development in 2025 : Product Development in 2025 : Life Stage : Childhood
• Expanded Thalassemia detection Panel • Lower Respiratory Panel • Antimicrobial Resistance Panel
• Inhouse PGTM Thalassemia / Expanded • Streptococcus Recovery
PGTM Panel • Tissue Extraction Growth monitoring,
Early cancer detection,
• LC-MS/MS Hormon/Steroid Panel • Customized Microbial Detection Panel
Rare Disease
FIRO the Analyst Product Development in 2025 :
• G6PD deficiency confirmatory test
“FIRO isn’t just a mascot, he • LC-MS/MS for Expanded New-Born
guides our innovation Screening
pipeline and keeps us • Carrier Genetic Screening
Life Stage : Womanhood
focused on delivering and
developing high-value Oncology Hormonal Health.
Product Development in 2025 : Cancer Screening,
diagnostics with real clinical
Companion testing /
impact especially for mothers • Immunohistochemistry Breast Panel targeted therapeutics
and children health needs.” • Immunohistochemistry Gastro Panel diagnostics
• Flowcytometry based analysis for
hematologic and solid tumor
Page 13
Diagnos has transformed from B2B Diagnostics to a Hybrid Model with direct to patient
clinical services focusing on metabolic and women’s Health Clinic as centers of Excellence
Metabolic Clinic
Metabolic clinic designed to address rising burden of chronic, non
communicable diseases, particularly in aging urban population. It converts
Diagnos lab data into longitudinal personalized care
Key Services:
• Risk Screening & Stratification
• Lab driven monitoring
• Personalized treatment pathway
“Preventive and long-term disease control for Aging Population”
Woman and Child health clinic
The woman and child health clinic positions Diagnos in the underserved yet
Diagnos Laboratory
critical segments of women’s and children’s care, combining preventive
Diagnostics service as the core enabler for clinical service screening with life-stage-specific support. This include hormonal health,
menopause treatment, maternal care and early childhood development and
pediatric diagnostics.
Key Services:
• Hormonal panel testing
• Pediatric diagnostics
• Hormone replacement and metabolic monitoring
“Addressing underserved women’s and children health needs across life
stages”
By Building these clinic around diagnostic data, Diagnos transform lab testing into proactive care bridging
diagnostics with long term clinical impact
Page 14
Integrating Genetics Testing and Advanced Smart Medical Checkup Within Community
Clinic Service Offering
Comprehensive Customized Treatment Continuous Monitoring and
Genetic Screening Protocol Treatment Improvement
Powered By
Customizations and Personalized Health
Programs
• Genetic Markers for Dietary Response
• Optimized Exercise Programs
• Screening Based on Personalized Health
Risks
Genetics Driven Screening to
understand:
Innovative Treatment through Collection of
Cohort Data:
• Personal Attribute Predispositions
to various Chronic Diseases • Development of internal Clinical data
registry for robust data collection and
• Precision Diagnostics and Health analysis
Conditions based on Risk Profile
• Refinement of treatment protocols
through cohort study using genetics profile
& Phenotype Data
Page 15
Thank You Contact Us Dessy Lapagu (Head of Corporate Finance & Investor Relation) +62817-0877-749 / dessy.lapagu@diagnos.co.id
Names mentioned 4 people and organisations named in the text · linked when the evidence is strong
Extraction attempts how the parser did, and what it refused
Nothing structured was extracted from this document — the attempts below say why.
No extraction attempted yet.